2023 Was a tricky 12 months with the biopharma field, with several providers downsizing and restructuring their workforces to remain afloat. You'll find signs of Restoration, as mergers and acquisitions picked up over the pharmaceutical and life sciences business while in the latter Element of 2023 and also have ongoing https://sites.google.com/view/bio-sites/blog